# Evaluation of Abbreviated Versus Conventional Course of Dabigatran Etexilate Before Electric Cardioversion in Patients With Atrial Fibrillation (RE-SOUND Study)

Study · id `cardio:ct-nct03975062` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03975062](<https://clinicaltrials.gov/study/NCT03975062>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03975062

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

## Technical summary

Registry record NCT03975062. Randomized; single masking; primary purpose prevention. Start 2017-12-28 (actual); primary completion 2020-12-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT03975062, source copy `cardio:ctgov-nct03975062-2019-06-05`, retrieved 2026-10-26)
- Started: 2017-12-28 (actual) (ClinicalTrials.gov record NCT03975062, source copy `cardio:ctgov-nct03975062-2019-06-05`, retrieved 2026-10-26)
- Primary completion: 2020-12-30 (anticipated) (ClinicalTrials.gov record NCT03975062, source copy `cardio:ctgov-nct03975062-2019-06-05`, retrieved 2026-10-26)
- Completion: 2020-12-30 (anticipated) (ClinicalTrials.gov record NCT03975062, source copy `cardio:ctgov-nct03975062-2019-06-05`, retrieved 2026-10-26)
- Countries: Russia (ClinicalTrials.gov record NCT03975062, source copy `cardio:ctgov-nct03975062-2019-06-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03975062-2019-06-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of Abbreviated Versus Conventional Course of Dabigatran Etexilate Before Electric Cardioversion in Patients With Atrial Fibrillation (RE-SOUND Study)
- Acronym: RE-SOUND
- Condition: Atrial Fibrillation
- Intervention (Drug): dabigatran etexilate
- Lead sponsor: Ural State Medical University
- Lead sponsor class: OTHER
- Collaborator: Boehringer Ingelheim
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as a collaborator: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

## Provenance

Content hash: f6bb3aaded7a2f92d687dafd4077cf4dcc5ce0c828d3e558de3d4df33f01cc6b
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
